Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing
Sónia A. Melo(Universidade do Porto), Manel Esteller(Institut d'Investigació Biomédica de Bellvitge), Alberto Villanueva(Institut d'Investigació Biomédica de Bellvitge), Raghu Kalluri(The University of Texas MD Anderson Cancer Center), Simona Rossi(The University of Texas MD Anderson Cancer Center), Àlvaro Aytés(Bellvitge University Hospital), Fernando Setién(Bellvitge University Hospital), Oriol Casanovas(Institute of Agrifood Research and Technology), Sara Puertas(Bellvitge University Hospital), Santiago Ropero(Spanish National Cancer Research Centre), Verónica Dávalos(Josep Carreras Leukaemia Research Institute), Carlo M. Croce(The Ohio State University), Cristina Ivan(The University of Texas MD Anderson Cancer Center), Cátia Moutinho(Bellvitge University Hospital), Riccardo Spizzo(The University of Texas MD Anderson Cancer Center), Laia Simó‐Riudalbas(Bellvitge University Hospital), F. Javier Carmona(Institut d'Investigació Biomédica de Bellvitge), Jordi Carrère(Bellvitge University Hospital), George A. Calin(National Cancer Institute), August Vidal(Bellvitge University Hospital)
Cited by 255
Related Papers
The basics of epithelial-mesenchymal transition
|Journal of Clinical Investigation|2009|10.1k
The role of MicroRNAs in human cancer
|Signal Transduction and Targeted Therapy|2016|2.5k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k